Viking Therapeutics, Inc.
VKTX
$31.32
-$0.40-1.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 23.90% | 31.03% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.37% | 67.14% | |||
| Operating Income | 0.37% | -67.14% | |||
| Income Before Tax | -0.42% | -73.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -0.42% | -73.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -0.42% | -73.66% | |||
| EBIT | 0.37% | -67.14% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 0.93% | -71.09% | |||
| Normalized Basic EPS | 0.97% | -71.14% | |||
| EPS Diluted | 0.93% | -71.09% | |||
| Normalized Diluted EPS | 0.97% | -71.14% | |||
| Average Basic Shares Outstanding | 1.37% | 1.50% | |||
| Average Diluted Shares Outstanding | 1.37% | 1.50% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||